Here is a list of recommended readings about therapeutic ketamine, organized by topic. (This list will be updated periodically.) Please think of this list as a “tasting menu” of various important aspects of therapeutic ketamine treatment. For an exhaustive list of reference materials, please go to PubMed. On this website, you can also find a list of books about therapeutic ketamine, and articles that cite Dr. Bennett specifically.
OVERVIEW & HISTORY
Bennett, R. (2019). Paradigms of ketamine treatment. MAPS Bulletin, 29(1).
https://maps.org/news/bulletin/articles/436-maps-bulletin-spring-2019-vol-29,-no-1/7718-paradigms-of-ketamine-treatment-spring-2019
Domino, E. (1965). Taming the Ketamine Tiger. Republished in Anesthesiology (Sept 2010, vol 113), 678-684.
https://doi.org/10.1097/ALN.0b013e3181ed09a2
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. M., … Zarate, C. A. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry (03/17/21).
doi.org/10.1176/appi.ajp.2020.20081251
Oaklander, M. (2017). New hope for depression. TIME.
https://time.com/magazine/us/4876068/august-7th-2017-vol-190-no-6-u-s/
Ryan, W. C., Marta, C. J., & Koek, R. J. (2014). Ketamine and depression: A review. International Journal of Transpersonal Studies, 33(2), 40–74. DOI: 10.24972/ijts.2014.33.2.40
http://dx.doi.org/10.24972/ijts.2014.33.2.40
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., & Nemeroff, C. B. (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 74(4), 399-405. DOI: 10.1001/jamapsychiatry.2017.0080
https://adaa.org/sites/default/files/Ketamine%20JAMA%20Journal%20Article%20-%20Charlie%20Nemeroff.pdf
Sewell, A. (2007). Ketamine: Peril and promise. MAPS Bulletin, XVII (1).
https://maps.org/news-letters/v17n1-html/ketamine-peril_and_promise.html
Thielking, M. (2018). Is the ketamine boom getting out of hand? Scientific American, 09/26/18.
https://www.scientificamerican.com/article/is-the-ketamine-boom-getting-out-of-hand/
DISSOCIATIVE & PSYCHEDELIC EXPERIENCE
Krupitsky, E. M., & Grinenko, A. Y. (1997). Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. Journal of psychoactive drugs, 29(2), 165-183.
https://doi.org/10.1080/02791072.1997.10400185
Kungurtsev, I. (1991). “Death-rebirth” psychotherapy with ketamine. The Albert Hoffman Foundation Bulletin.
http://whale.to/b/kungurtsev.html
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., et al. (2014). Do the dissociative side effects of ketamine mediate its antidepressant effects? Journal of Affective Disorders, 159, 56-61.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065787/
Mathai, D., Mathew, S. J., Storch, E. A., & Kosten, T. R. (2018). Revisiting the hallucinogenic potential of ketamine. Psychiatric Times, 35(6).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094990/
Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020). The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. Journal of Affective Disorders, 264, 123-129.
https://doi.org/10.1016/j.jad.2019.12.023
COMBINING KETAMINE WITH PSYCHOTHERAPY
Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019). Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy, Journal of Psychoactive Drugs, 51(2), 189-198. DOI: 10.1080/02791072.2019.1587556
https://www.tandfonline.com/doi/full/10.1080/02791072.2019.1587556
Gold, V. & Sienknecht, E. (2020) Ketamine-assisted psychotherapy online? Psychedelic Support, 06/19/2020.
www.psychedelic.support/resources/ketamine-assisted-psychotherapy-online/
Greenway, K. T., Garel, N., Jerome, L. & Feduccia, A. (2020). Integrating psychotherapy and psychopharmacology: Psychedelic-assisted psychotherapy and other combined treatments. Expert Review of Clinical Pharmacology.
https://doi.org/10.1080/17512433.2020.1772054
Katzman, J. (2018). Rapid depression remission and the “therapeutic bends” with ketamine-assisted psychotherapy. Psychedelics Today.
https://www.healingrealmscenter.com/blog/rapid-depression-remission-and-the-therapeutic-bends
Kolp, E., Young, S. M., Freidman, H., Krupitsky, E., Jansen, K., & O’Connor, L. (2007). Ketamine-enhanced psychotherapy: Preliminary clinical observations on its effects in treating death anxiety. International Journal of Transpersonal Studies, 26(1), 1–17.
http://dx.doi.org/10.24972/ijts.2007.26.1.1
Wilkinson, S. T., Wright, D., Fasula, M. K., Fenton, L., Griepp, M., Ostroff, R. B., & Sanacora, G. (2017). Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychotherapy and Psychosomatics, 86(3), 162–167. DOI: 10.1159/000457960
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516265/
YOUNGER & OLDER PATIENTS
Cullen, K. R., Amatya, P., Roback, M. G., Albott, C. S., Westlund Schreiner, M., Ren, Y., … & Reigstad, K. (2018). Intravenous ketamine for adolescents with treatment-resistant depression: an open-label study. Journal of child and adolescent psychopharmacology, 28(7), 437-444. DOI: 10.1089/cap.2018.0030
https://www.ncbi.nlm.nih.gov/pubmed/30004254
Gardner, C. (2017). Case report reveals successful treatment of adolescent depression with ketamine. Yale School of Medicine.
https://medicine.yale.edu/news-article/14682/
George, D., Gálvez, V., Martin, D., Kumar, D., Leyden, J., Hadzi-Pavlovic, D.,…& Loo, C. (2017). Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression. The American Journal of Geriatric Psychiatry, 25(7), 1199-1209. DOI: 10.1016/j.jagp.2017.06.007
https://www.sciencedirect.com/science/article/abs/pii/S1064748117303512?via%3Dihub
Turban, J. (2017). The ketamine breakthrough for suicidal children. Scientific American.
https://www.scientificamerican.com/article/the-ketamine-breakthrough-for-suicidal-children/
Zarrinnegar, P., Kothari, J., & Cheng, K. (2019). Successful use of ketamine for the treatment of psychotic depression in a teenager. Journal of Child and Adolescent Psychopharmacology, 29(6), 472-473. DOI: 10.1089/cap.2019.0028
https://www.ncbi.nlm.nih.gov/pubmed/31161948
POST-TRAUMATIC STRESS DISORDER
Liriano, F., Hatten, C., & Schwartz, T. L. (2019). Ketamine as treatment for post-traumatic stress disorder: A review. Drugs in context, 8, 212305. DOI: 10.7573/dic.212305
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457782/
Ross, C., Jain, R., Bonnett, C. J., & Wolfson, P. (2019). High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Annals of Clinical Psychiatry, 31(4), 271-279.
https://www.ncbi.nlm.nih.gov/pubmed/31675388
OBSESSIVE-COMPULSIVE DISORDER
Rodriguez, C. I., Kegeles, L. S., Flood, P., & Simpson, H. B. (2011). Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. The Journal of Clinical Psychiatry, 72(4), 567–569. DOI: 10.4088/JCP.10l06653
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727240/
Rodriguez, C. I., Wheaton, M., Zwerling, J., Steinman, S. A., Sonnenfeld, D., Galfalvy, H., & Simpson, H. (2016). Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? An open-label trial. The Journal of Clinical Psychiatry, 77(3), 408–409. DOI: 10.4088/JCP.15l10138
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544939/
SUBSTANCE USE DISORDERS
Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014). Therapeutic infusions of ketamine: Do the psychoactive effects matter? Drug and Alcohol Dependence, 136, 153–157. DOI :10.1016/j.drugalcdep.2013.12.019
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091719/
Dakwar E., Nunes, E.V., Hart, C.L., Hu, M.C., Foltin, R.W., & Levin, F. R. (2018) A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology, 142, 270-276. DOI: 10.1016/j.neuropharm.2018.01.005.
https://europepmc.org/article/PMC/6033686
Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M.,… & Levin, F. R. (2019). A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. American Journal of Psychiatry, 176(11), 923-930. DOI: 10.1016/j.neuropharm.2018.01.005
https://doi.org/10.1176/appi.ajp.2019.18101123
Jones, J. L., Mateus, C. F., Malcolm, R. J., Brady, K. T., & Back, S. E. (2018). Efficacy of ketamine in the treatment of substance use disorders: A Systematic Review. Frontiers in psychiatry, 9, 277. DOI: 10.3389/fpsyt.2018.00277
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094990/
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002). Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. Journal of Substance Abuse Treatment, 23, 273-283. DOI: 10.1016/s0740-5472(02)00275-1
https://www.researchgate.net/publication/10978647_Ketamine_psychotherapy_for_heroin_addiction_Immediate_effects_and_two-year_follow-up
Lalanne, L., Nicot, C., Lang, J. P., Bertschy, G., & Salvat, E. (2016). Experience of the use of ketamine to manage opioid withdrawal in an addicted woman: a case report. BMC Psychiatry, 16(1), 395. DOI: 10.1186/s12888-016-1112-2
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105239/
Rothberg, R., L., Azhari, N., Haug, N., Dakwar, E. (2020) Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. Journal of Psychopharmacology, 12/13/2020. DOI: 10.1177/0269881120970879
https://journals.sagepub.com/doi/abs/10.1177/0269881120970879
SUICIDALITY
Calabrese, L. (2019). Titrated serial ketamine infusions stop outpatient suicidality and avert ER Visits and hospitalizations. International Journal of Psychiatry Research, 2(6), 1-12.
http://scivisionpub.com/pdfs/titrated-serial-ketamine-infusions-stop-outpatient-suicidality-and-avert-er-visits-and-hospitalizations-918.pdf
SIDE EFFECTS & SAFETY PROFILE
Acevedo-Diaz, E.E., Cavanaugh, G.W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C.A. Jr, & Park, L.T. (2019). Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. Journal of Affective Disorders.
https://doi.org/10.1016/j.jad.2019.11.028
Andrashko, V., Novak, T., Bunovsky, M., Klirova, M., Sos, P., & Horacek, J. (2020). The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication. Frontiers in Psychiatry, 08/28/2020. DOI: 10.3389/fpsyt.2020.00844
https://www.frontiersin.org/articles/10.3389/fpsyt.2020.00844/full
Feifel, D., Dadiomov, D., & Lee, K. (2020). Safety of repeated administration of parenteral ketamine for depression. Pharmaceuticals 2020, 13(7);
doi:10.3390/ph13070151
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018). Side-effects associated with ketamine use in depression: a systematic review. The Lancet Psychiatry, 5(1), 65-78. DOI: 10.1016/S2215-0366(17)30272-9
http://www.kaimacdonald.com/wp-content/uploads/2018/04/Short-2017-common-side-effects-with-ketamine-for-depression-w.pdf
Singh, J. B. (2019). Elevated blood pressure from Esketamine not major concern. Healio Psychiatry.
https://www.healio.com/psychiatry/depression/news/online/%7B563e1d7d-af5c-4152-9851-4d040a53751e%7D/elevated-blood-pressure-from-esketamine-not-major-concern
ESKETAMINE (SPRAVATO)
Anderson, P. (2019). FDA’s rapid approval of Esketamine for severe depression questioned. Medscape.
https://www.medscape.com/viewarticle/921248
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021). Comparative efficacy of racemic ketamine and esketamine for depression: A systemic review and meta-analysis. Journal of Affective Disorders (278) 542-55.
DOI: https://doi.org/10.1016/j.jad.2020.09.071
https://www.sciencedirect.com/science/article/pii/S016503272032766X
Ramos, M. A., Boyd, W., & Alpert, M. D. (2019). Opinion: The new ketamine-based antidepressant is a rip-off; Johnson & Johnson patented a form of the psychedelic with less research and a ridiculous price tag. VICE.
https://www.vice.com/en_us/article/pajkjy/opinion-the-new-ketamine-based-antidepressant-is-a-rip-off
Ross, E. L. & Soeteman, D. I. (2020). Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States. Psychiatric Services, 2020.
https://ps.psychiatryonline.org/doi/10.1176/appi.ps.201900625